COLORADO SPRINGS, Colo.,
Feb. 3, 2014 /PRNewswire/
-- Endocan Corporation (NASDAQ OTC: ENDO), a U.S. Company
specializing in cannabis and cannabinoid formulation-based health
and wellness solutions, provides shareholder guidance concerning
its consultant MDS, a subsidiary of Medbox, Inc., and the
multi-million dollar agreement for multi-state product release
licensing, medical cannabis dispensary management, and
cultivation.
"We are excited by the renewed energy with MDS. Endocan
looks forward to moving forward with the executives at MDS as an
industry leader in consulting and helping match entrepreneurs with
opportunities," stated Robert Kane,
CFO and SR VP of Business Development, Endocan Corporation.
"Endocan is positioned well to take advantage of these
opportunities."
As announced on August 20, 2013,
Endocan will be bringing proprietary cannabinoid-based products and
formulations to market in state-approved regulatory environments
with dispensaries to be branded by the Company while using the
advanced, patented 'Medbox' dispensing technology. Endocan's
multi-year, strategic growth agreement with Medicine Dispensing
Systems, a wholly owned subsidiary of Medbox, a publicly traded
company, establishes Endocan as the provider of scientific and
clinical expertise for multiple medical cannabis dispensaries and
cultivation facilities in the states of Arizona, California, Illinois, Massachusetts, Nevada, and Washington State.
This milestone agreement provides Endocan with the real and
concrete opportunity to develop premiere branding and to introduce
the Company's proprietary cannabinoid-based products and
formulations within each state's regulatory framework. Under
the agreement, as a part of each dispensary build-out, Endocan will
brand the operations through the use of the patented Medbox system.
Medbox technology and software allows for biometric patient and
employee identification, internal documentation and tracking of
dispensing services for internal accounting and compliance
purposes, and secure inventory management and control.
About Medicine Dispensing Systems, A Subsidiary of Medbox,
Inc.
Medbox was founded on the principle that all great
industries thrive when automated and regulated. Our wholly owned
subsidiary, Medicine Dispensing Systems has grossed
$13 million dollars since it began
doing business in 2010 and later allowed for an acquisition and
the establishment of a public company presence in Medbox,
Inc. [MDBX]. The company's founder and CEO have appeared in
interviews with CNN, ABCNews, Reuters, BBC, Fox Business, Bloomberg
TV, CNBC, Associated Press, NPR, and the company has
been featured in articles appearing in Newsweek, Bloomberg
BusinessWeek, Los Angeles Times,
Chicago Tribune, and the Wall Street Journal, as well as over
30 other news agencies around the world concerning its cutting-edge
products and services.
About Endocan Corporation
Endocan Corporation is currently developing new natural
cannabis-based products based on innovative formulations to utilize
the unique and potent benefits of the cannabis and hemp plants.
Medicinal properties of cannabis and hemp have been known and
applied for thousands of years. With the aid of scientific
research, Endocan Corporation is translating such knowledge into
development of effective cannabinoid formulation-based health and
wellness solutions as well as cosmeceutical, nutraceutical, and
food brands throughout the world. The Company's health and
wellness, nutritional, and cosmetics lines will address personal
needs and will evolve with the introduction of new formulations and
products, advancing the Company within the expanding
multibillion-dollar global market.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. The
Company does not undertake any duty nor does it intend to update
the results of these forward-looking statements.
Endocan Corporation
President
Dr. Dorothy Bray
info@endocan.com
www.endocan.com
+1.866.326.5595
Investment Inquiries
Robert Kane
CFO, Sr Vp of Business Development
robert.kane@endocan.com
+1.561.420.4824
SOURCE Endocan Corporation